Adjuvant modified FOLFIRINOX yields better survival than gemcitabine in pancreatic cancer

06:06 EST 8 Jan 2019 | ecancermedicalscience

By ecancer reporter Janet Fricker In resected pancreatic adenocarcinoma, adjuvant chemotherapy with a modified FOLFIRINOX led to longer disease free and overall survival than gemcitabine, reports a phase 3 French and Canadian study published in The New...

More From BioPortfolio on "Adjuvant modified FOLFIRINOX yields better survival than gemcitabine in pancreatic cancer"